Last reviewed · How we verify
NCT05002465
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer
trial testing 68Ga-PSMA-11 in Prostate Cancer. No longer available.
Quick facts
| Lead sponsor | Dana Mathews |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- 68Ga-PSMA-11 — full drug profile →
- Positron Emission Tomography/Computed Tomography
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →
- Prostate Cancer Recurrent — all drugs for Prostate Cancer Recurrent →
Sponsor
Dana Mathews — full company profile →
Who can join
18 and older, male only, with Prostate Cancer or Prostate Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to provide 68Ga Prostate Specific Membrane Antigen-11 (68Ga PSMA-11) for clinical use in the diagnosis, staging and restaging of prostate cancer using Positron Emission Tomography with Computed Tomography (PET/CT) prior to its full local Federal Drug Administration (FDA) approval. Extensive research has shown that 68Ga PSMA-11 PET/CT offers higher detection rate of metastatic disease in prostate cancer than the current standard of care usually used in staging and restaging prostate cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Role of [<sup>68</sup>Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review.
Caracciolo M, Castello A, Urso L, Borgia F, et al · · 2022 · cited 11× · PMID 36291820 · DOI 10.3390/cancers14205036
Verify or expand the search:
- PubMed search for NCT05002465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 68Ga-PSMA-11
Trials testing the same drug.
- NCT07365397 — Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer · NA · not yet recruiting
- NCT07117760 — Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer · Phase 1, PHASE2 · recruiting
- NCT06004661 — Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Nor · Phase 2 · recruiting
- NCT05983198 — Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT · Phase 1, PHASE2 · active not recruiting
- NCT05847348 — 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients · Phase 3 · recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Dana Mathews trials
Trials by the same sponsor.
- NCT04483414 — 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer · Phase 2 · withdrawn
- NCT04179968 — The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05002465 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana Mathews
- Last refreshed: 11 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05002465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing